Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
Explore this paper's citation graph
Summary
This therapy is efficacious and moderately well tolerated in HRPC and should be compared in a phase III trial with mitoxantrone and prednisone.
- Type
- article
- Published
- 2001-05-01
- Cited by
- 288
- References
- 23
- OpenAlex
- https://openalex.org/W1879747226
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25947911
Keywords
Estramustine, Docetaxel, Medicine, Prostate cancer, Refractory (planetary science)
References
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
- A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
- Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
- Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
- Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3
- HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate.
- Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
- Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
- Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo
- Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
- Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Cited by
- Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
- Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer
- Docetaxel for the treatment of prostate cancer.
- The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum.
- Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014.
- Age Dependent Analysis and Modeling of Prostate Cancer Data
- Stellenwert der neoadjuvanten Therapie vor radikaler Prostatektomie
- E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.
- An investigation of the effect of some stable nitroxide antioxidants in prostate cancer cells
- Chemotherapy in the Treatment of Prostate Cancer — The Past, the Present, and the Future
- A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma
- Effects of direct injection of dehydrated ethanol on PC3 human prostate cancer cells in nude mice: Preliminary study
- A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma
- Matriptase-2 and the biological behaviours of prostate cancer cells : a possible role for beta-catenin
- A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
- Clinical development of novel therapeutics for castration‐resistant prostate cancer
- Estramustine Phosphate Sodium
- The Epigenetic Silencing of PMP24 During the Progression of Prostate Cancer from an Androgen-Dependent to Androgen-Independent State in the LNCAP Cell Model: a Dissertation
- Assessing Outcomes in Prostate Cancer Clinical Trials: A 21st Century Tower of Babel
- Clinical and Preclinical Treatment Aspects of Castration Resistant Prostate Cancer (CRPC)
Related papers
- Treatment of androgen‐independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study
- Docetaxel in prostate cancer.
- Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
- Docetaxel (Taxotere) in hormone-refractory prostate cancer.
- Future directions in the treatment of androgen-independent prostate cancer.
- 159 INVITED Targeting MEK in tumors with BRAF and RAS mutations
- Docetaxel with estramustine for prostate cancer
- Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
- A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer
- Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.